avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated
Company profile
Ticker
RNA
Exchange
Website
CEO
Sarah Boyce
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Avidity Biosciences LLC, Avidity NanoMedicines LLC
SEC CIK
Corporate docs
Subsidiaries
Avidity Biosciences Ireland Limited ...
IRS number
461336960
RNA stock data
Latest filings (excl ownership)
D
$400.21 mm in equity / options / securities to be acquired, sold $400.21 mm, 45 investors
19 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
S-8
Registration of securities for employees
29 Feb 24
8-K
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
29 Feb 24
S-3ASR
Automatic shelf registration
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
28 Feb 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
Other Events
14 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
12 Dec 23
Latest ownership filings
4
ARTHUR A LEVIN
21 Mar 24
4
Michael F MacLean
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
ARTHUR A LEVIN
12 Mar 24
4
Sarah Boyce
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
Sarah Boyce
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 85.95 mm | 85.95 mm | 85.95 mm | 85.95 mm | 85.95 mm | 85.95 mm |
Cash burn (monthly) | 22.74 mm | 4.83 mm | 19.54 mm | 18.51 mm | 12.26 mm | 14.56 mm |
Cash used (since last report) | 136.03 mm | 28.91 mm | 116.88 mm | 110.69 mm | 73.35 mm | 87.10 mm |
Cash remaining | -50.08 mm | 57.03 mm | -30.93 mm | -24.74 mm | 12.60 mm | -1.15 mm |
Runway (months of cash) | -2.2 | 11.8 | -1.6 | -1.3 | 1.0 | -0.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 143 |
Opened positions | 18 |
Closed positions | 18 |
Increased positions | 62 |
Reduced positions | 40 |
13F shares | Current |
---|---|
Total value | 519.52 bn |
Total shares | 89.24 mm |
Total puts | 1.30 k |
Total calls | 45.40 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
FMR | 11.11 mm | $70.91 bn |
RTW Investments | 6.69 mm | $42.68 bn |
T. Rowe Price | 6.62 mm | $42.21 bn |
Ra Capital Management | 6.42 mm | $40.94 bn |
BLK Blackrock | 5.79 mm | $36.92 bn |
Cowen And | 5.63 mm | $35.91 bn |
Cowen Financial Products | 5.19 mm | $115.13 mm |
STT State Street | 4.16 mm | $26.54 bn |
Vanguard | 4.01 mm | $25.61 bn |
Avoro Capital Advisors | 2.51 mm | $16.01 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Mar 24 | Levin Arthur A | Common Stock | Sell | Dispose S | No | No | 23.9695 | 5,000 | 119.85 k | 14,830 |
19 Mar 24 | Levin Arthur A | Common Stock | Option exercise | Acquire M | No | No | 1.24 | 5,000 | 6.20 k | 19,830 |
19 Mar 24 | Levin Arthur A | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.24 | 5,000 | 6.20 k | 38,323 |
13 Mar 24 | MacLean Michael F | Common Stock | Sell | Dispose S | No | No | 24.519 | 40,000 | 980.76 k | 44,093 |
13 Mar 24 | MacLean Michael F | Common Stock | Option exercise | Acquire M | No | No | 8.82 | 40,000 | 352.80 k | 84,093 |
13 Mar 24 | MacLean Michael F | Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.82 | 40,000 | 352.80 k | 244,427 |
12 Mar 24 | Levin Arthur A | Common Stock | Sell | Dispose S | No | No | 22 | 2,641 | 58.10 k | 14,830 |
12 Mar 24 | Levin Arthur A | Common Stock | Sell | Dispose S | No | No | 22.0366 | 25,000 | 550.92 k | 17,471 |
12 Mar 24 | Levin Arthur A | Common Stock | Option exercise | Acquire M | No | No | 1.24 | 25,000 | 31.00 k | 42,471 |
12 Mar 24 | Levin Arthur A | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.24 | 25,000 | 31.00 k | 43,323 |
News
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
14 Mar 24
Cantor Fitzgerald Initiates Coverage On Avidity Biosciences with Overweight Rating, Announces Price Target of $60
14 Mar 24
American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday
5 Mar 24
A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
5 Mar 24
Chardan Capital Maintains Buy on Avidity Biosciences, Raises Price Target to $33
5 Mar 24
Press releases
Avidity Biosciences to Participate in Upcoming Investor Conferences
27 Mar 24
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Mar 24
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
4 Mar 24
Avidity Biosciences Honors Rare Disease Day®
29 Feb 24
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
29 Feb 24